Integrated Cellular and Molecular Diagnostics

What Integrated Cellular and Molecular Diagnostics does

Integrated Cellular and Molecular Diagnostics (ICMD) is a privately held, CAP-accredited clinical and molecular pathology laboratory founded in 2014 and headquartered in Greenbelt, Maryland, with main laboratory operations in Boca Raton, Florida. The company provides anatomic pathology, clinical pathology, and molecular diagnostics to local hospitals, physician groups, and ambulatory surgery centers across the Mid-Atlantic and Southeast United States, delivering diagnostic results within a stated 48-hour turnaround. Sub-specialty services span women's health (including the Prosigna FDA-approved breast cancer assay offered via Thomas Jefferson University), urology, gastroenterology, dermatology, primary care/internal medicine, and hematology/oncology, covering tests such as KRAS/BRAF gene testing, UroVysion FISH, HER2/neu FISH, immunohistochemistry, flow cytometry, cytogenomic array, and BioFire molecular panels.

ICMD's underlying technology is a conventional integrated diagnostic platform that combines anatomic, clinical, and molecular pathology workflows, with interface connectivity to most Electronic Medical Record and Practice Management Systems for order and results exchange. It operates advanced molecular capabilities through the BioFire platform and exclusive vendor relationships that the company states minimize healthcare costs for clients. The company is pursuing designation as a Molecular Center of Excellence by Ventana/Roche Diagnostics, which would place it among a small number of US reference laboratories with that credential.

The business model is fee-for-service laboratory testing billed to health insurance plans and healthcare providers, with revenue generated per test/specimen across the three integrated service lines. Go-to-market is direct enterprise field sales led by a VP of Business Development, supported by an operations/customer service team and a client portal for supply ordering and result retrieval. In May 2026, ICMD's parent company LabGenomics consolidated it and sibling QDx Pathology Services under the LabGenomics brand, unifying pathology and molecular testing capabilities into a single diagnostic platform while the underlying laboratory operations continue.

Name

Integrated Cellular and Molecular Diagnostics

Legal name

Integrated Cellular and Molecular Diagnostics

Website

https://icmdiagnostics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

ICMD is a privately held, CAP-accredited diagnostic laboratory providing anatomic, clinical, and molecular pathology services to hospitals, physician groups, and surgery centers across the Mid-Atlantic and Southeast US. Now operating under the LabGenomics brand following a May 2026 consolidation.

Ownership category

akta.pro rank

Product category

Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

akta.pro secondary industries

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI)

Keywords

• Molecular diagnostics services
• Anatomic pathology testing
• Clinical pathology laboratory
• Cancer genomic assays
• Diagnostic laboratory services

Headquarters

HQ city

Greenbelt

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Laboratory Services: Fee-for-service laboratory testing model providing anatomic pathology, clinical pathology, and molecular diagnostics to healthcare providers. Services are billed to health insurance plans or paid directly for out-of-pocket expenses.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Integrated Cellular and Molecular Diagnostics (ICMD) is a CAP-accredited clinical and anatomic pathology laboratory that delivers anatomic pathology, clinical pathology, and molecular diagnostics to healthcare providers. It offers sub-specialty testing across women's health, urology, gastroenterology, dermatology, primary care, and hematology/oncology, and provides specialized genomic assays such as the FDA-approved Prosigna breast cancer test.

Product overview

ICMD operates as a unified diagnostic laboratory providing comprehensive anatomic, clinical, and molecular pathology services. The core product portfolio consists of three integrated service lines: Anatomic Pathology Services (surgical pathology, cytopathology, histology), Clinical Pathology Services (chemistry, hematology, immunology, microbiology), and Molecular Diagnostics (PCR, gene testing, FISH, genomic analysis). These core services are delivered through multiple sub-specialty channels including Women's Health (with Prosigna breast cancer assay), Urology, Gastroenterology, Dermatology, Primary Care/Internal Medicine, and Hematology/Oncology. ICMD functions as the primary brand identity, formerly operating as Integrated Molecular Diagnostics before brand consolidation under LabGenomics.

Differentiator

Problem solved

Functional benefit

Products and services

• Anatomic Pathology Services Diagnostic examination of tissues and cells including surgical pathology, cytopathology, and histological analysis for disease diagnosis, provided to hospitals, physician groups, and surgery centers.
• Clinical Pathology Services Laboratory testing services including clinical chemistry, hematology, immunology, microbiology, urinalysis, coagulation, and therapeutic drug monitoring for healthcare providers.
• Molecular Diagnostics Advanced molecular testing including PCR, gene testing (KRAS, BRAF), fluorescent in-situ hybridization (FISH), cytogenetics, and genomic analysis for cancer diagnostics and personalized medicine.
• Women's Health Diagnostics Gynecologic tissue and cytology diagnostics including breast tissue analysis, featuring the Prosigna FDA-approved assay for breast cancer risk assessment.
• Urology Pathology Services Full genitourinary tract specimen processing including prostate, bladder, ureter, urethra, and kidney anatomic pathology with specialized testing including DNA ploidy analysis, UroVysion FISH, PCA3, and PSA testing.
• Gastroenterology Diagnostics GI specimen diagnostics including KRAS and BRAF gene testing, microsatellite instability/Lynch syndrome testing, and HER2/neu fluorescent in-situ hybridization.
• Dermatology Pathology Services Dermatological specimen handling including routine biopsies, Mohs surgical specimens, histochemical and immunohistochemical staining, and direct immunofluorescence testing.
• Primary Care / Internal Medicine Services Comprehensive clinical testing including general chemistry, hematology, therapeutic drug monitoring, coagulation, immunology, urinalysis, microbiology, infectious disease testing, prenatal services, hormone testing, allergy testing, and BioFire molecular testing.
• Hematology/Oncology Diagnostics Cancer diagnostic testing including immunohistochemistry, flow cytometry, fluorescent in-situ hybridization (FISH), cytogenetics, cytogenomic array (aCGH), and PCR/molecular diagnostics.
• Prosigna Breast Cancer Assay FDA-approved genomic assay for assessing risk in early-stage breast cancer, offered with support from Thomas Jefferson University.

Quantifiable outcome

• Diagnostic results delivered within 48 hours

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• LabGenomicsflagshipStrategic or Co-development Partner · 11 May 2026Integrated Molecular Diagnostics (IMD) transitioned to the LabGenomics brand as part of a strategic consolidation with QDx Pathology Services. This unifies pathology and molecular testing capabilities under a single identity to create a more comprehensive diagnostic platform.
• Ventana/Roche DiagnosticscoreStrategic or Co-development PartnerICMD is pursuing designation as one of the handful of reference laboratories in the nation designated as a Molecular Center of Excellence by Ventana/Roche Diagnostics. This would represent a significant quality recognition for the company's molecular diagnostics capabilities.
• Thomas Jefferson UniversitycoreTechnology or IntegrationWith support from Thomas Jefferson University, ICMD is one of the few laboratories in the nation able to provide Prosigna, an FDA-approved breast cancer genomics assay for assessing risk in early-stage breast cancer.
• National VendorscoreStrategic or Co-development PartnerICMD maintains exclusive relationships with national vendors which facilitates the minimization of healthcare costs for clients.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Quest Diagnostics: One of the largest U.S. reference laboratories offering full anatomic, clinical, and molecular pathology services to hospitals, physicians, and surgery centers — directly competing with ICMD on breadth, scale, and payer contracts.
• Laboratory Corporation of America (Labcorp): National clinical and anatomic pathology laboratory serving the same hospital, physician group, and surgery center segments as ICMD, with substantially greater scale and a comparable molecular diagnostics menu.
• Aurora Diagnostics (now part of Sonic Healthcare): National anatomic pathology platform acquired by Sonic Healthcare; directly comparable to ICMD in providing community-hospital and physician-group surgical pathology and molecular services across multiple sub-specialties.

Direct peers

• BioReference Laboratories: Specialty reference lab offering anatomic pathology, molecular diagnostics, and sub-specialty testing to clinicians; competes with ICMD in oncology, urology, women's health, and GI specialty niches.
• NeoGenomics Laboratories: Specialty oncology-focused clinical and anatomic pathology lab with strong molecular and cytogenetics capabilities — directly comparable to ICMD's hematology/oncology, FISH, and molecular service lines.
• PathGroup: Physician-led anatomic and clinical pathology lab serving hospitals, surgery centers, and physician practices across the Southeast and Mid-Atlantic — overlapping ICMD's regional service model and sub-specialty offerings.
• ARUP Laboratories: Major U.S. reference laboratory offering comprehensive anatomic, clinical, and molecular pathology with deep sub-specialty expertise; comparable to ICMD in test menu breadth and academic-grade pathologist talent.
• AmeriPath: Anatomic and clinical pathology provider serving hospitals, physicians, and surgery centers with sub-specialty expertise in dermatology, GI, urology, and oncology — closely matching ICMD's sub-specialty service model.

Emerging players

• Caris Life Sciences: Molecular profiling and precision oncology lab that overlaps ICMD's oncology molecular testing, FISH, and personalized medicine services with a higher-complexity commercial focus.
• Guardant Health: Liquid biopsy and molecular oncology company whose molecular diagnostic capabilities intersect ICMD's oncology molecular testing menu, especially in KRAS, BRAF, and breast cancer assays like Prosigna.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/icmd_lab

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integrated Cellular and Molecular Diagnostics